Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07293546) titled 'Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)' on Dec. 16, 2025.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: FOXG1 Research Foundation

Condition: FOXG1 Syndrome

Intervention: Genetic: FRF-001

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: April 2026

Target Sample Size: 12

To know more, visit https://clinicaltrials.gov/study/NCT07293546

Disclaimer: Curated by HT Syndication....